Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777243 | 0.82 | RNASEH1 (0.32) | LMNATRPA1PTGS1CACNA1CALDH1A1 | |
| SCHEMBL27769971 | 0.82 | ALDH1A1 (0.34) | LMNATRPA1PTGS1CACNA1CALDH1A1 | |
| SCHEMBL1774865 | 0.81 | NPC1 (0.33) | — | |
| SCHEMBL6865501 | 0.80 | NPC1 (0.32) | LMNAPTGS1ALDH1A1HTTHIF1A | |
| SCHEMBL8576130 | 0.78 | PTGS2 (0.33) | LMNAPTGS1ALDH1A1HTTHIF1A | |
| SCHEMBL1777470 | 0.78 | PTGS2 (0.33) | LMNAPTGS1ALDH1A1HTTHIF1A | |
| SCHEMBL10180211 | 0.77 | PDK2 (0.30) | — | |
| SCHEMBL7456700 | 0.76 | IDH1 (0.41) | — | |
| SCHEMBL15067062 | 0.73 | LMNA (0.38) | LMNATRPA1PTGS1CACNA1CALDH1A1 | |
| SCHEMBL677008 | 0.71 | LMNA (0.37) | LMNATRPA1PTGS1CACNA1CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455511-B2 | Pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2424913-A1 | CASTABLE POLYUREA COMPOSITIONS FOR GOLF BALL COVERS | Dow Global Technologies LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7932259-B2 | Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| WO-2010126931-A1 | CASTABLE POLYUREA COMPOSITIONS FOR GOLF BALL COVERS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-1787992-B1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-04-29 | — | — | EP | disclosed |
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | TASHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
| EP-1781652-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH TETRAHYDROPYRIDINE AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1758903-A1 | PYRROLOPYRAMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006001511-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | WO | disclosed |
| WO-2006001501-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH TETRAHYDROPYRIDINE AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | WO | disclosed |
| US-20050209253-A1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1467997-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004058767-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | WO | disclosed |
| EP-1140900-A4 | PYRAZOLE COMPOUNDS AND USES THEREOF | PPD DISCOVERY INC (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1140900-A2 | PYRAZOLE COMPOUNDS AND USES THEREOF | PPD DISCOVERY, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039083-A2 | PYRAZOLE COMPOUNDS AND USES THEREOF | PPD DISCOVERY, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | HRH2, HRH4, CRHR1 | LMNA 4857/4885TRPA1 2256/4885PTGS1 213/4885 |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH4, CRHR1 | LMNA 4838/4885TRPA1 1799/4885PTGS1 212/4885 |
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | CRHR1, CRHR2, HRH4 | LMNA 4804/4885TRPA1 1041/4885PTGS1 299/4885 |
| US-20050209253-A1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | HRH2, HRH4, HRH1 | LMNA 4844/4885TRPA1 1866/4885PTGS1 232/4885 |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | CRHR1, HRH2, CRHR2 | LMNA 4809/4885TRPA1 956/4885PTGS1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.